Annual report pursuant to Section 13 and 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)

v3.22.2.2
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)
12 Months Ended
Jun. 30, 2022
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance June 30, 2019

$

(9,537)

$

(73,983)

$

(83,521)

Other comprehensive income (loss) before reclassifications

 

(7,179)

 

(9,963)

 

(17,142)

Reclassification from loss on derivatives to interest expense, net of taxes(1)

3,464

3,464

Balance June 30, 2020(3)

$

(13,253)

$

(83,946)

$

(97,199)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne(2)

 

100

 

32,848

 

32,948

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)

 

6,960

 

 

6,960

Balance as of June 30, 2021(3)

$

(6,193)

$

(51,098)

$

(57,291)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne(2)

 

9,403

 

(32,171)

 

(22,768)

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)

 

4,859

4,859

Balance as of June 30, 2022(3)

$

8,069

$

(83,269)

$

(75,200)

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,352 to interest expense and recorded a related tax benefit of $1,493 during fiscal 2022. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021.  The Company reclassified $4,503 to interest expense and a related tax benefit tax of $1,040 during fiscal 2020.  

(2) Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $70 and $103 attributable to the non-controlling interest in Eminence as of June 30, 2022, and June 30, 2021, respectively.
(3) The Company had a net deferred tax liability of $2,480 as of June 30, 2022, and net deferred tax benefits of $1,908 and $4,058 as of June 30, 2021, and June 30, 2020, respectively.